362 completed, 67 unknown, 50 recruiting, 50 terminated. 603 Phase 2, 104 Phase 1, 53 Phase 3.
Follow Parkinson Disease: new trials by email Literature Review of Parkinson Disease trials Research Report on Parkinson Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD) | Phase 2 | Suspended | Ergun Y. Uc | 120 | 2028-07-01 | 2026-10-09 |
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease | Phase 2 | Not yet recruiting | Mthera Pharma Co., Ltd. | 120 | 2027-09-01 | 2026-10-16 |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
| A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD) AB-1005 - Parkinson Disease | Phase 2 | Not yet recruiting | Bayer | 8 | 2027-01-25 | 2026-07-29 |
| Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease Talineuren, Placebo - Parkinson Disease | Phase 2 | Not yet recruiting | InnoMedica Schweiz AG | 40 | 2027-01-01 | 2026-10-30 |
| Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), Advanced Primary PD | Phase 1 / Phase 2 | Not yet recruiting | Kanglin Biotechnology (Hangzhou) Co., Ltd. | 12 | 2027-01-01 | 2026-11-16 |
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease 60 milligrams of ENERGI-F705 Tablets, Placebo tablets, 120 milligrams of ENERGI-F705 Tablets - Parkinson's Disease (PD) | Phase 2 | Not yet recruiting | Energenesis Biomedical Co., Ltd. | 105 | 2026-12-01 | 2026-07-02 |
| A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), PD | Phase 1 / Phase 2 | Not yet recruiting | Kanglin Biotechnology (Hangzhou) Co., Ltd. | 12 | 2026-12-01 | 2026-11-10 |
| Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism Intrathecal (IT), Intravenous - Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere | Phase 2 | Not yet recruiting | Biocells Medical | 120 | 2026-11-23 | 2026-03-13 |
| Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease RO7568282, Placebo - Parkinson's Disease | Phase 2 | Recruiting | Hoffmann-La Roche | 474 | 2026-11-11 | 2026-11-16 |
| Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA) Prescriptive Infusion Algorithm, AB-1005 - PARKINSON DISEASE (Disorder) | Phase 2 | Not yet recruiting | AskBio Inc | 18 | 2026-11-01 | 2026-10-29 |
| Lemborexant on Perioperative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep Brain Stimulation Lemborexant 5 mg, Placabo - Parkinson Disease (PD), Sleep Initiation and Maintenance Disorders | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 128 | 2026-11-01 | 2026-10-29 |
| Prevent Cognitive Decline in GBA-associated Parkinson's Disease Prasinezumab, Sodium Chloride - Parkinson's Disease | Phase 2 | Recruiting | University Hospital Tuebingen | 120 | 2026-10-01 | 2026-10-23 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease UX-DA003 - Parkinson's Disease | Phase 1 / Phase 2 | Recruiting | Shanghai UniXell Biotechnology Co., Ltd | 12 | 2026-09-24 | 2026-11-04 |
| RESvEraTrol in Parkinson's Disease (RESET) Trans-Resveratrol - Parkinson's Disease | Phase 2 | Recruiting | Georgetown University | 30 | 2026-09-17 | 2026-09-18 |
| A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy VIM0423, VIM0423 Placebo - PARKINSON DISEASE (Disorder) | Phase 2 | Recruiting | Vima Therapeutics | 80 | 2026-09-15 | 2026-11-10 |
| Terazosin And Metabolic Engagement in Parkinson's Disease Terazosin Hydrochloride, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Withdrawn | Nandakumar Narayanan | 2026-09-01 | 2026-10-07 |
Showing 20 of 603. Sign in to see all of them.
Dyskinesias (44) · Movement Disorders (33) · Neurodegenerative Diseases (20) · Parkinsonian Disorders (18) · Brain Diseases (12) · Central Nervous System Diseases (12) · Cognitive Dysfunction (12) · Depression (12) · Tremor (10) · Alzheimer Disease (9) · Anxiety Disorders (8) · Dementia (8) · Dyskinesia, Drug-Induced (8) · Nervous System Diseases (8)
Synucleinopathies (600) · Basal Ganglia Diseases (597) · Nervous System Diseases (595) · Brain Diseases (591) · Central Nervous System Diseases (591) · Parkinsonian Disorders (585) · Neurodegenerative Diseases (583) · Movement Disorders (570) · Pathological Conditions, Signs and Symptoms (98) · Signs and Symptoms (81) · Neurologic Manifestations (66) · Mental Disorders (61) · Neurocognitive Disorders (26) · Behavior (20) · Pathologic Processes (20)
Levodopa (31) · carbidopa, levodopa drug combination (23) · Carbidopa (12) · Apomorphine (10) · istradefylline (8) · mavoglurant (8) · Sodium Chloride (7) · entacapone (7) · Donepezil (6) · Pramipexole (6) · perampanel (6) · rotigotine (6) · Droxidopa (5) · Saline Solution (5) · Sugars (5)
National Institute of Neurological Disorders and Stroke (NINDS) (20) · Institute for Neurodegenerative Disorders (9) · Chang Gung Memorial Hospital (7) · Eisai Inc. (7) · Biogen (6) · Kyowa Kirin Co., Ltd. (6) · Novartis (6) · Tanta University (6) · University Hospital, Toulouse (6) · Impax Laboratories, LLC (5) · Integrative Research Laboratories AB (5) · Novartis Pharmaceuticals (5) · Oregon Health and Science University (5) · Otsuka Pharmaceutical Co., Ltd. (5) · University College, London (5)
United States (293) · France (66) · Germany (51) · Canada (46) · United Kingdom (46) · Italy (37) · Spain (36) · China (28) · Israel (25) · Japan (24) · Poland (23) · Austria (19) · Netherlands (17) · Sweden (15) · Taiwan (14)
Danna Jennings, MD (6) · Kyoji Imaoka, Mr (4) · John G. Nutt, MD (3) · Neil Sussman, MD (3) · Abraham Lieberman, MD (2) · Ann Neale, RN (2) · Baorong Zhang, MD (2)
PMID 36602886, PMID 38588457, PMID 40680102, PMID 31356217, PMID 17941858, PMID 21484867, PMID 24412048, PMID 24711047, PMID 27214258, PMID 36849448, PMID 38072889, PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11076832, PMID 11400186, PMID 11724917, PMID 12222941, PMID 12465055, PMID 12498954, PMID 12771261, PMID 12904089, PMID 1454205, PMID 15175402, PMID 15331239, PMID 15345186, PMID 15590952, PMID 15645531, PMID 15779234, PMID 15956161, PMID 16025231, PMID 16214880, PMID 16376913, PMID 16442563, PMID 16715205, PMID 16837857, PMID 17190953, PMID 17353373, PMID 17881719, PMID 17940108, PMID 18079166, PMID 18268187, PMID 18349024, PMID 18413464, PMID 18442107, PMID 18474731, PMID 18519872, PMID 18546344
2016 (6), 2023 (5), 2008 (4), 2015 (4), 2009 (3), 2017 (3), 2025 (3), 2018 (2), 2019 (2), R01NS021062 (2), R01NS099535 (2), U01NS043128 (2), 1UG3NS133515-01A1 (1), 2004 (1), I01RX003397 (1)